v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - DIAMIR BIOSCIENCES CORP - USD ($)
9 Months Ended 12 Months Ended
Feb. 28, 2026
Feb. 28, 2025
May 31, 2025
May 31, 2024
Total revenue $ 190,355 $ 631,729 $ 631,729 $ 1,319,531
Operating costs and expenses        
Cost of service revenue 93,016    
Research and development 337,255 548,486 650,591 1,156,860
General and administrative 1,006,054 503,157 624,388 614,074
Total operating costs and expenses 1,436,325 1,051,643 1,274,979 1,770,934
Loss from operations (1,245,970) (419,914) (643,250) (451,403)
Other income/(expense)        
Other income 809,542    
Interest expense (87,960) (59,450) 82,046 48,599
Total other income/(expense) 721,582 (59,450) 82,046 48,599
Net loss before income taxes (524,388) (479,364) (725,296) (500,002)
Income tax (benefit) expense (174,546) 14,346 17,939 114,403
Net loss $ (349,842) $ (493,710) $ (743,235) $ (614,405)
Net loss per common share, basic (in Dollars per share) $ (0.08) $ (0.11) $ (0.17) $ (0.14)
Net loss per common share, diluted (in Dollars per share) $ (0.08) $ (0.11) $ (0.17) $ (0.14)
Weighted average number of common shares outstanding        
Basic (in Shares) 4,440,891 4,440,891 4,440,891 4,440,891
Diluted (in Shares) 4,440,891 4,440,891 4,440,891 4,440,891
Service revenue        
Total revenue $ 130,355    
Grant revenue        
Total revenue 531,729 $ 531,729 $ 1,319,531
Other revenue        
Total revenue $ 60,000 $ 100,000 $ 100,000